Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORIMUNO19-ECU: Eculizumab in COVID-19 Pneumonia
NCT04346797Phase 2Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2020
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Eculizumab with Standard of Care (2 arms). Primary endpoints: Survival without needs of intubation at 14 days and Change in organ failure at 3 days. Status: unknown.
02
Drugs
eculizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04346797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04346797.